NAMPT (Nicotinamide Phosphoribosyltransferase) Inhibitors Markets, 2040 with Profiles of Antengene Therapeutics, Aqualung Therapeutics, Karyopharm Therapeutics, OncoTartis, and Onxeo
Tags:
DUBLIN, Dec. 19, 2022 /PRNewswire/ -- The "NAMPT Inhibitors Market, Distribution by Type of Molecule, Therapeutic Area, Indication, Route of Administration, Line of Treatment, and Key Geographical Regions: Industry Trends and Global Forecasts, 2022-2040" report has been added to ResearchAndMarkets.com's offering.
The "NAMPT Inhibitors Market" report features an extensive study of the current landscape, offering an informed opinion on the likely adoption of NAMPT inhibitors in the healthcare domain, till 2040. The report features an in-depth analysis, highlighting the capabilities of various stakeholders engaged in this market space.
Globally, cancer is one of the leading causes of death; in 2020, about 10 million cancer related deaths were reported. Further, according to a study published in American Cancer Society Journal, by 2040, the number of cancer cases is projected to reach over 28 million, indicating a cumulative growth of nearly 47%, since 2020.
The continuous growth in the number of cancer patients imposes a huge burden, in terms of finances as well as resources, on the overall healthcare system. In this context, it is worth mentioning that the annual expenditure associated with cancer care is more than USD 200 billion, in the US alone.
Given the fact that majority of the current treatment options for cancer have proven to be inadequate, especially for late-stage cancers, there is a high demand for highly effective therapeutics. Over time, many research studies have demonstrated that NAMPT (Nicotinamide Phosphoribosyl Transferase) can interfere with the metabolism of NAD+, which is known to be the fuel for tumor cells; this notion has encouraged several researchers to conduct extensive studies for the development of novel and efficacious drug candidates, such as NAMPT inhibitors.
NAMPT inhibitors are being evaluated to target a wide range of indications, primarily focusing on oncological disorders. Given the encouraging research outcomes, the domain has attracted the attention of many private and public investors who have made investments worth more than USD 650 million, since 2018. Driven by the increasing RandD activity, promising clinical data and financial support from investors, the NAMPT inhibitors market is anticipated to grow at a commendable pace in the mid to long-term.
The report also features the likely distribution of the current and forecasted opportunity related to NAMPT inhibitors market across type of molecule (small molecules and biologics), therapeutic area (oncological and respiratory disorders), indication (non-hodgkin lymphoma, hodgkin lymphoma, acute respiratory distress syndrome, and acute myeloid leukemia), route of administration (oral and intravenous), line of treatment (1st line and 2nd line), and key geographical regions.
Scope of the Report
A detailed overview of the current market landscape of NAMPT targeting drug candidates that are currently being researched in pre-clinical and clinical studies, featuring an elaborate analysis of such therapies based on several relevant parameters, such as phase of development (preclinical, phase I, phase I/II and phase II), type of molecule (small molecules and biologics), route of administration (oral and intravenous), target indication (acute myeloid leukemia, acute respiratory distress syndrome, hodgkin lymphoma, and non-hodgkin lymphoma), line of treatment (1st line and 2nd line) and type of therapy (monotherapy and combination therapy).
An elaborate analysis of recent partnerships and collaborations that have been inked by several stakeholders engaged in the domain of NAMPT inhibitors since 2022, including a brief description of the various partnership models adopted (including product development and commercialization agreement, product development, manufacturing and commercialization agreement, mergers and research and development agreement).
An insightful analysis of recent funding instances that have been reported by several players engaged in the NAMPT inhibitors domain, including details on the year of funding, amount received and type of funding (awards / grants, venture series, initial public offering, secondary offerings, debt financing and other equity).
An in-depth analysis on various grants, since the year 2022, received by players engaged in this field based on year of award, amount awarded, funding institute, activity code, focus area, recipient organizations, support period, type of grant application, and prominent program officers.
An insightful company competitiveness analysis of NAMPT inhibitor targeting therapy developers, based on several relevant parameters, such as the firm's portfolio strength (taking into consideration number of drugs in pipeline, phase of development and type of molecule), partnership strength (in terms of the number of partnerships established and partnership year) and funding strength (in terms of number of funding instances, amount of funding, year of funding, type of funding and number of lead investors).
Elaborate profiles of prominent players that are engaged in the development of NAMPT inhibitors, featuring a brief overview of the company, along with information on financials, product portfolio, patent portfolio, recent developments and an informed future outlook.
A detailed analysis of several peer-reviewed, scientific articles related to research on NAMPT inhibitors, over last 12 years, based on several relevant parameters, such as year of publication, type of publication and popular keywords.
An analysis of the global events attended by industry players, based on several relevant parameters, such as year of event, event platform, type of event, leading presenters (in terms of number of participations) and leading players (in terms of number of participations).
An analysis of prevalent and emerging trends related to NAMPT inhibitors as represented on the social media platform, Twitter, based on several relevant parameters, such as year of tweet, top users and emerging focus areas.
An in-depth analysis focused on NAMPT inhibitors that failed to progress to later stages of clinical development, based on various relevant parameters, such as phase of discontinuation, target indication, route of administration and type of molecule.
A proprietary analysis on various competitive strategies that can be implemented by drug developers engaged in this domain, to expedite the FDA approval process for their proprietary products; it includes information on several relevant parameters, such as clinical evidence, awards / grants, research findings, partnerships, other financial support received and others.
A detailed market forecast analysis, highlighting the likely growth of the NAMPT inhibitors in the healthcare market, over the period 2022-2040, based on several relevant parameters, such as target patient population, likely launch year of therapy candidates, approval timeline of drugs, likely price points and expected rates of adoption, across various geographical regions.
Frequently Answered Questions
Key Topics Covered:
1. EXECUTIVE SUMMARY
2. INTRODUCTION2.1. Overview of NAMPT Inhibitors2.2. Key Historical Events Related to NAMPT Inhibitors2.3. NAMPT Inhibitors: Recent Activity2.4. NAMPT Inhibitors: Mechanism of Action2.5. NAMPT Inhibitors: Key Target Indications
3. MARKET LANDSCAPE3.1. NAMPT Inhibitors: Pipeline Review3.2. NAMPT Inhibitors: Developer Landscape
4. PARTNERSHIPS AND COLLABORATIONS4.1. NAMPT Inhibitors: Partnerships and Collaborations
5. FUNDING AND INVESTMENTS5.1. NAMPT Inhibitors: Funding and Investments
6. GRANTS ANALYSIS6.1. Scope and Methodology6.2. NAMPT Inhibitors: List of Grants Awarded by National Institutes of Health
7. COMPANY COMPETITIVENESS7.1. Key Assumptions and Parameters7.2. Methodology7.3. Benchmarking of Portfolio Strength7.4. Benchmarking of Partnership Activity7.5. Benchmarking of Funding Activity7.6. Benchmarking of Portfolio Strength7.7. NAMPT Inhibitors: Company Competitiveness Analysis
8. COMPANY PROFILES8.1. Antengene Therapeutics8.2. Aqualung Therapeutics8.3. Karyopharm Therapeutics8.4. OncoTartis8.5. Onxeo
9. PUBLICATION ANALYSIS9.1. Methodology and Key Parameters9.2. NAMPT Inhibitors: List of Publications
10. GLOBAL EVENTS ANALYSIS10.1. Methodology and Key Parameters10.2. NAMPT Inhibitors: List of Global Events
11. SOCIAL MEDIA ANALYSIS11.1. Methodology and Key Parameters
12. DRUG FAILURE ANALYSIS12.1. Methodology and Key Parameters12.2. NAMPT Inhibitors: List of Failed Drug Candidates
13. FDA APPROVAL STRATEGIES13.1. Methodology and Key Parameters13.2. General Reasons for Failure of Trials Focused on NAMPT Inhibitors and Key Strategies Adopted by Developers13.3. Drug Specific Business Models followed by Company13.4. Analysis of Drug Candidates by Business Model
14. MARKET FORECAST AND OPPORTUNITY ANALYSIS14.1. Key Assumptions and Parameters14.2. Forecast Methodology14.3. Global NAMPT Inhibitors Market, 2027-204014.4. List of Forecasted Drugs14.4.1. OT-82, OncoTartis14.4.2. ALT-100, Aqualung Therapeutics14.4.3. ATG-019, Antengene Therapeutics14.4.4. KPT-9274, Karyopharm Therapeutics14.5. NAMPT Inhibitors Market: Analysis by Type of Molecule, 2027 and 204014.6. NAMPT Inhibitors Market: Analysis by Therapeutic Area, 2027 and 204014.7. NAMPT Inhibitors Market: Analysis by Target Indication, 2027 and 204014.8. NAMPT Inhibitors Market: Analysis by Line of Treatment, 2027 and 204014.9. NAMPT Inhibitors Market: Analysis by Route of Administration, 2027 and 204014.10. NAMPT Inhibitors: Market Share of Key Players14.11. NAMPT Inhibitors Market: Analysis by Geography, 2030-2040
15. EXECUTIVE INSIGHTS
16. APPENDIX 1: LIST OF FIGURES
17. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS
For more information about this report visit https://www.researchandmarkets.com/r/x7h6mv
Media Contact:Research and MarketsLaura Wood, Senior Manager[email protected] For E.S.T Office Hours Call +1-917-300-0470For U.S./CAN Toll Free Call +1-800-526-8630For GMT Office Hours Call +353-1-416-8900 U.S. Fax: 646-607-1907Fax (outside U.S.): +353-1-481-1716
Logo: https://mma.prnewswire.com/media/539438/Research_and_Markets_Logo.jpg
SOURCE Research and Markets
More news releases in similar topics
Cision Distribution 888-776-0942
from 8 AM - 9 PM ET
